Journal
PHARMACOGENOMICS JOURNAL
Volume 15, Issue 2, Pages 135-143Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2014.45
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R00CA138914]
- National Natural Science Foundation [81372216]
Ask authors/readers for more resources
Different combinations of 5-fluorouracil (5-FU), oxaliplatin, irinotecan and other newly developed agents have been used to treat colorectal cancer. Despite the advent of new treatment regimens, the 5-year survival rate for metastatic colorectal cancer remains low (similar to 10%). Knowing the drug sensitivity of a given tumor for a particular agent could significantly impact decision making and treatment planning. Biomarkers are proven to be successful in characterizing patients into different response groups. Using survival prediction analysis, we have identified three independent gene signatures, which are associated with sensitivity of colorectal cancer cells to 5-FU, oxaliplatin or irinotecan. On the basis of the three gene signatures, three score systems were developed to stratify patients from sensitive to resistance. These score systems exhibited robustness in stratify patients in two independent clinical studies. Patients with high scores in all three drugs exhibited the lowest survival.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available